These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Optimal DAPT duration: each in their own time. Hillegass WB; Brott BC Catheter Cardiovasc Interv; 2015 Jan; 85(1):41-2. PubMed ID: 25521927 [No Abstract] [Full Text] [Related]
49. [Duration and Timing of Initiation of Therapy With Platelet P2Y12 Inhibitors in the Treatment of Patients With Acute Coronary Syndrome]. SHalaev SV; Safiullina ZM Kardiologiia; 2018 Mar; (3):54-62. PubMed ID: 29782272 [TBL] [Abstract][Full Text] [Related]
50. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Gurbel PA; Kuliopulos A; Tantry US Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):500-12. PubMed ID: 25633316 [TBL] [Abstract][Full Text] [Related]
51. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice? Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423 [TBL] [Abstract][Full Text] [Related]
53. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry. Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM; JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884 [TBL] [Abstract][Full Text] [Related]
54. Looking beyond antiplatelet effect of P2Y12 inhibitors: is there anything to see? Sabbah M; Lønborg J; Engstrøm T; Nepper-Christensen L Int J Cardiol; 2020 Dec; 320():25. PubMed ID: 32652211 [No Abstract] [Full Text] [Related]
55. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice. Sibbing D; Orban M; Massberg S Hamostaseologie; 2013; 33(1):9-15. PubMed ID: 23299202 [TBL] [Abstract][Full Text] [Related]
56. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Dorsam RT; Murugappan S; Ding Z; Kunapuli SP Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029 [No Abstract] [Full Text] [Related]
57. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study. Nakamura M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Ikeda Y; Saito S Int J Cardiol; 2015 Mar; 182():541-8. PubMed ID: 25679803 [TBL] [Abstract][Full Text] [Related]
58. Prasugrel hydrochloride for the treatment of acute coronary syndromes. Lhermusier T; Waksman R Expert Opin Pharmacother; 2015 Mar; 16(4):585-96. PubMed ID: 25633751 [TBL] [Abstract][Full Text] [Related]
59. Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. Bazemore TC; Nanna MG; Rao SV J Thromb Thrombolysis; 2017 Oct; 44(3):303-315. PubMed ID: 28730406 [TBL] [Abstract][Full Text] [Related]